Skip to content
RushPR News – Lifestyle
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
←
Previous Page
1
2